# Research Protocol

## Project: OmniLatent

**Subtitle:** Learning Generalizable, Robust, and Interpretable Multimodal Representations from Biomedical Data

**Version:** 2.1  
**Status:** Active Development  
**Author:** AIResearcher20  
**Last Updated:** July 2026

---

# Table of Contents

1. Vision
2. Scientific Motivation
3. Problem Statement
4. Expected Scientific Contributions
5. Research Questions
6. Scientific Hypotheses
7. Project Objectives
8. Scope
9. Success Criteria

---

# 1. Vision

The rapid expansion of high-throughput biomedical technologies has fundamentally transformed modern biomedical research.

Large-scale initiatives such as **The Cancer Genome Atlas (TCGA)** have generated unprecedented collections of heterogeneous patient data, including transcriptomic, genomic, molecular, and clinical measurements. These resources provide an exceptional opportunity to study human disease from multiple complementary biological perspectives.

Despite these advances, most existing machine learning approaches remain narrowly optimized for individual prediction tasks. Models are commonly developed to maximize task-specific performance while learning representations that are rarely reusable beyond the original application.

OmniLatent addresses this limitation by pursuing a fundamentally different objective.

Rather than constructing another predictive model, OmniLatent aims to develop a **general-purpose multimodal representation learning framework** capable of discovering compact latent representations that capture the underlying biological organization shared across heterogeneous biomedical modalities.

The learned patient representations are expected to be:

- biologically meaningful,
- clinically informative,
- transferable across cancer types,
- robust to incomplete observations,
- interpretable by biomedical researchers,
- reusable across diverse downstream analyses.

Ultimately, OmniLatent seeks to establish a modular scientific framework capable of supporting precision medicine research while remaining reproducible, extensible, and computationally transparent.

---

# 2. Scientific Motivation

Biomedical datasets are becoming increasingly multimodal.

Modern patient cohorts routinely contain complementary information describing multiple aspects of disease biology, including:

- RNA sequencing
- Clinical variables
- Somatic mutations
- DNA methylation
- Copy number variation
- Histopathology
- Medical imaging
- Emerging spatial and single-cell technologies

However, these heterogeneous data sources are frequently analyzed independently or combined using simple feature concatenation strategies.

Such approaches often ignore complex relationships between modalities and may fail to capture the complementary biological information distributed across different molecular layers.

Representation learning provides an alternative computational paradigm.

Instead of optimizing directly for a predefined prediction task, representation learning seeks to discover low-dimensional latent variables that preserve biologically meaningful variation while remaining useful across multiple downstream analyses.

This paradigm is particularly attractive for biomedical research because it enables one learned representation to support diverse scientific objectives, including:

- patient stratification,
- disease subtype discovery,
- survival analysis,
- biomarker identification,
- cross-cohort comparison,
- transfer learning.

OmniLatent is motivated by the hypothesis that high-quality multimodal latent representations provide a more faithful description of patient biology than modality-specific feature spaces.

---

# 3. Problem Statement

Although biomedical datasets continue to increase in both scale and complexity, existing computational approaches frequently exhibit one or more important limitations.

Common limitations include:

- dependence on a single molecular modality,
- limited biological interpretability,
- poor robustness to incomplete observations,
- limited transferability across diseases,
- optimization for narrowly defined prediction tasks,
- weak reproducibility across experimental settings.

These limitations reduce the scientific utility of learned representations and restrict their applicability to broader biomedical discovery.

Consequently, there remains a need for a computational framework capable of learning reusable multimodal patient representations that preserve clinically and biologically relevant information while supporting diverse downstream analyses.

OmniLatent is designed to address this challenge.

---

# 4. Expected Scientific Contributions

The anticipated scientific contributions of OmniLatent include:

- A modular framework for multimodal biomedical representation learning.

- A reproducible computational pipeline for patient-level embedding generation.

- A systematic evaluation framework for assessing biological quality, robustness, and transferability of learned representations.

- Quantitative evidence regarding the advantages of multimodal representation learning over classical and unimodal baselines.

- An open-source software platform that facilitates future research in biomedical artificial intelligence.

---

# 5. Research Questions

The development of OmniLatent is guided by a set of scientific questions that collectively evaluate the effectiveness, robustness, interpretability, and transferability of multimodal representation learning.

Rather than focusing solely on predictive performance, these questions investigate whether the learned latent representations capture biologically meaningful information that generalizes across datasets and downstream analyses.

---

## RQ1 — Multimodal Representation Learning

**How can heterogeneous biomedical modalities be integrated into a unified latent representation while preserving complementary biological information?**

---

## RQ2 — Multimodal versus Unimodal Learning

**Does multimodal representation learning produce higher-quality patient embeddings than representations learned from individual modalities alone?**

---

## RQ3 — Nonlinear versus Linear Representation Learning

**Do nonlinear latent representations learned by deep neural networks provide more informative biological organization than classical linear dimensionality reduction methods such as Principal Component Analysis (PCA)?**

---

## RQ4 — Biological Meaningfulness

**Do the learned latent representations preserve clinically and biologically meaningful patient structure?**

This question will be investigated through associations with:

- molecular subtypes,
- clinical variables,
- genomic alterations,
- survival outcomes.

---

## RQ5 — Representation Reusability

**Can a single learned latent representation support multiple downstream biomedical analyses without task-specific retraining?**

Representative downstream tasks include:

- clustering,
- visualization,
- subtype characterization,
- survival analysis,
- clinical association studies.

---

## RQ6 — Cross-Cancer Generalization

**Can representations learned from one cancer cohort generalize to independent cancer types without retraining the encoder?**

---

## RQ7 — Modality Contribution

**What is the relative contribution of each biomedical modality to the quality of the shared latent representation?**

---

## RQ8 — Robustness

**How robust are learned representations when one or more modalities are missing, noisy, or partially corrupted?**

---

# 6. Scientific Hypotheses

The following hypotheses will be evaluated throughout the project.

---

## H1

Multimodal representations outperform RNA-only representations across multiple downstream evaluation tasks.

---

## H2

Deep nonlinear representation learning provides more informative latent spaces than classical linear dimensionality reduction techniques.

---

## H3

The learned latent space preserves biologically meaningful organization that reflects clinically relevant patient heterogeneity.

---

## H4

Patient embeddings learned from one cancer type remain transferable to unseen cancer cohorts without additional encoder optimization.

---

## H5

Multimodal latent representations remain informative under incomplete or partially corrupted multimodal observations.

---

## H6

The shared latent space captures complementary biological information that cannot be recovered from individual modalities independently.

---

# 7. Project Objectives

The primary objective of OmniLatent is to establish a reusable framework for multimodal biomedical representation learning.

Specific objectives include:

### Scientific Objectives

- Learn biologically meaningful patient representations.
- Integrate heterogeneous biomedical modalities into a unified latent space.
- Quantify the biological relevance of learned embeddings.
- Evaluate representation robustness under realistic biomedical data imperfections.
- Assess cross-cancer transferability of learned representations.

---

### Engineering Objectives

- Develop a modular software framework.
- Ensure full experimental reproducibility.
- Support configuration-driven experimentation.
- Enable future architectural extensions with minimal software modification.
- Produce publication-quality software and documentation.

---

# 8. Scope

The initial release of OmniLatent intentionally focuses on a well-defined scientific scope.

---

## Included in Version 1

### Data

- TCGA datasets
- RNA sequencing
- Clinical variables
- Somatic mutation profiles

### Methods

- Deep representation learning
- Multimodal Autoencoder
- Cross-cancer evaluation
- Biological interpretation
- Open-source implementation

---

## Excluded from Version 1

The following topics are considered future extensions rather than immediate development goals.

### Architectures

- Transformer-based models
- Foundation models
- Contrastive learning
- Graph Neural Networks

### Modalities

- Histopathology images
- Radiology imaging
- DNA methylation
- Proteomics
- Spatial transcriptomics

### Infrastructure

- Federated learning
- Distributed training
- Clinical deployment

Restricting the initial scope allows the framework to mature while maintaining scientific rigor and implementation quality.

---

# 9. Success Criteria

The project will be considered successful if it satisfies the following scientific and engineering criteria.

---

## Scientific Success

- OmniLatent consistently outperforms PCA and unimodal AutoEncoder baselines.
- Learned embeddings demonstrate biologically meaningful organization.
- Cross-cancer transfer experiments demonstrate measurable representation transferability.
- Robustness experiments confirm stability under incomplete multimodal inputs.
- Multiple downstream analyses can utilize the same learned latent representation.

---

## Engineering Success

- All experiments are fully reproducible.
- Software architecture remains modular and maintainable.
- Experimental outputs are automatically documented.
- The repository reaches publication-ready quality.
- The framework can serve as a foundation for future biomedical AI research.

---

# 10. Dataset Selection

The initial development of OmniLatent is intentionally centered on a well-characterized cancer cohort to ensure methodological rigor before expanding toward broader biomedical applications.

---

## Primary Development Cohort

The first implementation is developed using the **TCGA Breast Invasive Carcinoma (TCGA-BRCA)** cohort.

This cohort is selected because it satisfies several desirable characteristics for multimodal representation learning:

- one of the largest TCGA cancer cohorts,
- high-quality RNA sequencing data,
- comprehensive clinical annotations,
- publicly available somatic mutation profiles,
- established molecular subtype labels,
- well-documented survival information,
- extensive use in computational oncology literature.

The BRCA cohort therefore provides an appropriate environment for developing and validating the first version of OmniLatent.

---

## External Validation Cohorts

Generalization is evaluated using independent TCGA cohorts that are not used during model training.

Current validation cohorts include:

- TCGA-LUAD
- TCGA-KIRC

Future releases may additionally evaluate:

- TCGA-COAD
- TCGA-LIHC
- TCGA-HNSC
- Pan-Cancer cohorts

---

# 11. Data Modalities

Version 1 integrates three complementary sources of biomedical information.

---

## RNA Sequencing

Transcriptomic measurements provide quantitative estimates of gene expression across thousands of genes.

Scientific role:

- characterize cellular activity,
- identify biological programs,
- capture functional molecular variation.

---

## Clinical Variables

Clinical information describes observable patient characteristics including:

- demographic variables,
- tumor stage,
- survival outcomes,
- treatment information (when available).

Scientific role:

- clinical interpretation,
- downstream biological evaluation,
- phenotype association.

---

## Somatic Mutation Profiles

Binary mutation profiles summarize genomic alterations observed within each patient.

Scientific role:

- characterize genomic heterogeneity,
- complement transcriptomic information,
- improve multimodal patient representation.

---

# 12. Experimental Design

The scientific evaluation of OmniLatent consists of multiple complementary experiments.

Each experiment investigates one aspect of representation quality.

---

## Experiment 1 — Linear vs Nonlinear Representation Learning

Comparison:

- PCA
- OmniLatent

Objective:

Determine whether nonlinear multimodal representations better capture biological organization than classical linear dimensionality reduction.

---

## Experiment 2 — Unimodal vs Multimodal Learning

Comparison:

- RNA AutoEncoder
- OmniLatent

Objective:

Quantify the contribution of multimodal integration.

---

## Experiment 3 — Biological Interpretation

Objective:

Evaluate whether latent representations preserve meaningful biological structure through association with:

- molecular subtype,
- tumor stage,
- mutation burden,
- clinical phenotypes.

---

## Experiment 4 — Survival Analysis

Objective:

Determine whether patient embeddings preserve prognostic information.

Representative analyses include:

- Kaplan–Meier estimation,
- Log-rank testing,
- Concordance Index.

---

## Experiment 5 — Cross-Cancer Transfer

Training cohort:

- TCGA-BRCA

Evaluation cohorts:

- TCGA-LUAD
- TCGA-KIRC

The encoder remains frozen throughout evaluation.

No additional optimization is performed.

---

## Experiment 6 — Robustness Analysis

Objective:

Evaluate representation stability under incomplete multimodal observations.

Representative scenarios include:

- missing RNA,
- missing clinical information,
- missing mutation profiles.

---

## Experiment 7 — Noise Injection

Objective:

Evaluate latent representation stability under controlled perturbations.

Examples include:

- Gaussian noise,
- random feature corruption,
- feature masking.

---

## Experiment 8 — Ablation Study

Objective:

Quantify the contribution of each modality.

Each modality is removed independently while monitoring representation quality degradation.

---

# 13. Model Development Strategy

OmniLatent is intentionally developed as an extensible representation learning framework rather than a fixed neural architecture.

The representation learning component may evolve while preserving the surrounding software infrastructure.

Current development roadmap:

Version 1

→ Multimodal AutoEncoder

↓

Version 2

→ Variational AutoEncoder

↓

Version 3

→ Contrastive Representation Learning

↓

Version 4

→ Foundation Representation Learning

Throughout this evolution:

- preprocessing remains unchanged,
- evaluation remains unchanged,
- downstream analyses remain unchanged,

allowing fair comparison across representation learning paradigms.

---

# 14. Baseline Methods

Scientific evaluation requires comparison against established reference methods.

Current baseline methods include:

| Method | Scientific Purpose |
|---------|--------------------|
| PCA | Linear dimensionality reduction |
| RNA AutoEncoder | Nonlinear unimodal representation |
| MOFA+ | Multimodal latent factor analysis |
| OmniLatent | Proposed multimodal framework |

Future benchmark methods may include:

- DeepCCA
- MOGONET
- Graph-based multimodal models
- Contrastive representation learning approaches

The baseline framework is intentionally extensible to support future comparative studies.

---

# 15. Evaluation Framework

The primary objective of evaluation is not merely to measure predictive performance, but to determine whether the learned latent representations capture biologically meaningful, clinically relevant, and transferable information.

Evaluation is therefore organized into complementary dimensions that collectively assess representation quality.

---

## 15.1 Representation Quality

The intrinsic quality of the learned latent space will be evaluated using unsupervised clustering metrics.

Primary metrics include:

- Silhouette Score
- Davies–Bouldin Index
- Calinski–Harabasz Index

These metrics quantify:

- cluster compactness,
- cluster separation,
- latent space organization.

---

## 15.2 Biological Evaluation

Representation quality must also be evaluated from a biological perspective.

Latent representations will therefore be analyzed for associations with:

- molecular subtype,
- tumor stage,
- mutation burden,
- clinical phenotypes,
- patient similarity.

The objective is to determine whether latent structure reflects meaningful biological organization rather than purely statistical variation.

---

## 15.3 Survival Evaluation

To investigate clinical relevance, latent representations will be evaluated using survival analysis.

Representative analyses include:

- Kaplan–Meier estimation,
- Log-rank testing,
- Concordance Index (C-index).

These analyses assess whether patient embeddings preserve prognostic information.

---

## 15.4 Visualization

Low-dimensional visualization supports qualitative interpretation of learned representations.

Visualization techniques include:

- PCA
- UMAP
- Cluster visualization
- Heatmaps
- Latent feature exploration

Visualization is considered complementary to quantitative evaluation rather than a substitute for statistical analysis.

---

# 16. Statistical Analysis Plan

Scientific conclusions should be supported by statistically rigorous evaluation.

Accordingly, the following practices will be adopted throughout the project.

---

## Experimental Repetition

Experiments will be repeated using multiple random seeds whenever appropriate.

Performance will be summarized as:

Mean ± Standard Deviation

rather than single-run results.

---

## Statistical Significance

Appropriate statistical tests will be performed whenever comparisons between competing methods are required.

Where applicable, results will include:

- confidence intervals,
- statistical significance,
- effect size estimation.

---

## Reporting Strategy

Both positive and negative findings will be reported.

Scientific transparency takes precedence over selective performance reporting.

---

# 17. Robustness Evaluation

Real-world biomedical datasets are frequently incomplete or noisy.

A clinically useful representation learning framework should therefore remain informative under imperfect conditions.

---

## Missing Modality Experiments

Robustness will be evaluated under systematic removal of individual modalities.

Representative scenarios include:

- missing RNA sequencing,
- missing clinical variables,
- missing mutation profiles.

---

## Noise Injection

Controlled perturbation experiments will investigate sensitivity to degraded measurements.

Examples include:

- Gaussian noise,
- feature corruption,
- random masking.

---

## Objective

Determine whether the learned latent representation remains stable despite incomplete or corrupted multimodal observations.

---

# 18. Cross-Cancer Generalization

One of the central scientific goals of OmniLatent is to determine whether learned representations capture general biological principles rather than cancer-specific statistical patterns.

---

## Training

Training is performed exclusively using:

- TCGA-BRCA

---

## Evaluation

The trained encoder remains frozen.

Without additional optimization, embeddings are generated for:

- TCGA-LUAD
- TCGA-KIRC

Future studies may include additional TCGA cohorts.

---

## Scientific Objective

Successful transfer would suggest that the latent space captures biological structure that extends beyond a single disease cohort.

Cross-cancer generalization therefore serves as a critical measure of representation quality.

---

# 19. Interpretability

Representation quality cannot be assessed solely through numerical performance.

The biological meaning of the learned latent space is considered a primary research objective.

Interpretability analyses include:

- latent feature importance,
- association with clinical variables,
- molecular subtype enrichment,
- mutation burden analysis,
- visualization of latent dimensions,
- downstream biological interpretation.

Interpretability is treated as a fundamental property of useful biomedical representations rather than an optional post hoc analysis.

---

# 20. Reproducibility

OmniLatent is developed according to the principles of reproducible computational science.

Every experiment should be independently reproducible using publicly available software, documented configurations, and deterministic computational pipelines.

---

## Reproducibility Practices

The framework employs:

- fixed random seeds,
- configuration-driven experiments,
- version-controlled source code,
- deterministic preprocessing whenever possible,
- documented software environments,
- automatic experiment logging.

---

## Experimental Artifacts

Each experiment should automatically preserve:

- configuration files,
- software version,
- trained model,
- learned embeddings,
- evaluation metrics,
- generated figures,
- execution logs.

Experimental artifacts should remain immutable and independently reproducible throughout the lifetime of the project.


---

# 21. Repository Organization

OmniLatent is organized as a modular research software framework in which scientific experiments, reusable source code, documentation, and experimental outputs remain clearly separated.

The repository follows a structure that promotes readability, reproducibility, and future extensibility.

```text
OmniLatent/

configs/
data/
    raw/
    processed/
    metadata/

src/
    data/
    models/
    training/
    evaluation/
    visualization/
    utils/

results/
figures/
paper/
docs/
tests/
notebooks/
```

The `src/` directory contains reusable production code, whereas notebooks are reserved exclusively for exploratory analysis and visualization.

---

# 22. Development Milestones

Project development is organized into sequential research phases.

| Phase | Status |
|--------|--------|
| Research Design | ✅ Completed |
| Software Architecture | ✅ Completed |
| Repository Organization | ✅ Completed |
| Data Acquisition | 🟡 In Progress |
| Data Preprocessing | ⚪ Planned |
| Baseline Models | ⚪ Planned |
| OmniLatent Version 1 | ⚪ Planned |
| Representation Evaluation | ⚪ Planned |
| Cross-Cancer Validation | ⚪ Planned |
| Manuscript Preparation | ⚪ Planned |

Each milestone represents a reproducible scientific deliverable rather than merely a software implementation stage.

---

# 23. Expected Deliverables

Upon completion, OmniLatent is expected to provide the following scientific and software deliverables.

## Scientific Deliverables

- biologically meaningful patient embeddings,
- systematic benchmarking against baseline methods,
- cross-cancer transfer evaluation,
- robustness analysis,
- publication-quality figures,
- reproducible experimental results.

## Software Deliverables

- modular open-source framework,
- reproducible preprocessing pipeline,
- configurable training pipeline,
- reusable evaluation framework,
- complete project documentation,
- publication-ready repository.

---

# 24. Potential Risks and Mitigation

Potential technical and scientific risks have been identified together with corresponding mitigation strategies.

| Risk | Mitigation Strategy |
|------|----------------------|
| Missing patient identifiers | Careful harmonization across modalities |
| High-dimensional transcriptomic data | Normalization and feature filtering |
| Overfitting | Early stopping and regularization |
| Limited transferability | Cross-cancer evaluation |
| Missing modalities | Robustness experiments |
| Dataset heterogeneity | Standardized preprocessing pipeline |

Recognizing these risks early supports more reliable scientific conclusions.

---

# 25. Ethical Considerations

OmniLatent exclusively utilizes publicly available and de-identified biomedical datasets.

The framework does not process personally identifiable information (PII).

All analyses comply with the data usage policies associated with the original repositories.

The project is intended solely for scientific research and methodological development and is **not** designed as a clinical decision-support system.

Consequently, no clinical recommendations should be inferred directly from the generated representations without independent biomedical validation.

---

# 26. Future Directions

The architecture has been intentionally designed to support incremental methodological evolution.

Future extensions may include:

## Representation Learning

- Variational Autoencoders
- Contrastive Representation Learning
- Self-Supervised Learning
- Foundation Models

## Neural Architectures

- Graph Neural Networks
- Transformer-based encoders
- Hybrid multimodal architectures

## Additional Modalities

- DNA methylation
- Copy Number Variation
- Proteomics
- Histopathology
- Radiology
- Spatial Transcriptomics
- Single-cell sequencing

## Large-Scale Evaluation

- Pan-Cancer TCGA analysis
- External biomedical cohorts
- Multi-institutional validation

The surrounding software infrastructure is expected to remain stable while representation learning algorithms evolve over future releases.

---

# Guiding Principles

The development of OmniLatent is guided by the following principles.

1. Scientific questions drive methodological choices.
2. Reproducibility is a mandatory requirement.
3. Biological interpretability is a primary objective.
4. Generalization must be demonstrated rather than assumed.
5. Software quality should support long-term scientific reuse.
6. Modularity enables future methodological evolution.
7. Open science practices maximize transparency and reproducibility.

---

# Conclusion

OmniLatent is conceived as a reusable scientific framework rather than a task-specific deep learning model.

Its primary objective is to develop biologically meaningful, clinically informative, and transferable multimodal patient representations while maintaining high standards of scientific rigor, software engineering, and computational reproducibility.

The framework is intentionally designed to evolve beyond its initial implementation, providing a stable foundation for future advances in multimodal biomedical representation learning.

This research protocol serves as the governing reference for the scientific design, software implementation, and experimental methodology of the OmniLatent project.

